SAGE - Sage Therapeutics Reports Phase 2 Huntington's Data | Benzinga
Sage Therapeutics, Inc. (NASDAQ:SAGE) shares are trading lower on Tuesday. The company eelier announced results from its Phase 2 Huntington’s Disease clinical study.
The Details: On Tuesday before the market opened, Sage Therapeutics announced topline results from its Phase 2 SURVEYOR Study, which met its primary endpoint demonstrating a statistically significant difference as measured by the HD-CAB composite score at ...